President and Chief Executive Officer
Margaret (Margie) McGlynn, President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI) since July 2011, leads a global team of scientists, clinicians and advocates and fosters innovation, flexibility and collaboration in the quest to develop safe, effective, accessible, preventive HIV vaccines for use throughout the world.
Under McGlynn’s leadership, IAVI has reshaped its AIDS vaccine research and advocacy programs to focus on particular areas where the organization can add unique value to the field, working in close partnership with other researchers, organizations, governments and communities. Having joined IAVI's Board of Directors in July 2010, McGlynn continues to serve on the Board in an ex-officio role.
McGlynn is currently a member of the board of the Global HIV Vaccine Enterprise and the External Advisory Committee of the HIV Vaccine Trials Network (HVTN), and previously served on the board and executive committee of the GAVI Alliance, a public-private partnership dedicated to bringing life-saving vaccines against common infectious diseases to people across the developing world.
Prior to IAVI, she spent 26 years at Merck, where her responsibilities covered multiple disease areas and geographies, including vaccines and anti-infectives. As head of Merck’s global vaccines and infectious diseases business, she oversaw a US$ 7 billion portfolio of products and the launch of important new vaccines and anti-infective agents including Gardasil, the first vaccine developed to prevent cervical cancer, and Isentress, the first integrase inhibitor marketed to treat HIV. She also helped launch several initiatives to provide people in developing countries with access to Merck’s vaccines and antiretroviral medications.
McGlynn holds a Bachelor’s degree in Pharmacy and an MBA in Marketing, both from the State University of New York at Buffalo.